期刊文献+

灯盏花和还原型谷胱甘肽治疗抗结核药物性肝损的观察 被引量:1

下载PDF
导出
摘要 目的:观察灯盏花素注射液与还原型谷胱甘肽治疗抗结核药物性肝损的疗效。方法:当发现药物性肝损且达到停药标准时,实验组1每天用灯盏花素注射液30 ml加入浓度为10%的葡萄糖溶液250 ml中静滴;实验组2每天用1.8 g还原型谷胱甘肽加入生理盐水250 ml中静脉滴注;实验组3每天联合应用1.8 g还原型谷胱甘肽和30 ml灯盏花素注射液分别加入生理盐水250 ml中静脉滴注。对照组则以维生素C 2 g替代,各组疗程均25—30天。疗程满后再次复查肝功以评定疗效,对比各组的疗效,用X2检验两者的差异显著性。结果:灯盏花素和还原型谷胱甘肽治疗抗结核药物性肝损有效率比对照组均有升高,两者存在显著性差异(P<0.05),而两者联用可增加治疗的有效率。结论:提示灯盏花素和还原型谷胱甘肽对治疗抗结核药物性肝损有效。
作者 刘琨 黄冬生
机构地区 广州市胸科医院
出处 《中药材》 CAS CSCD 北大核心 2006年第5期519-521,共3页 Journal of Chinese Medicinal Materials
  • 相关文献

参考文献14

  • 1程书权.抗结核药物致肝损害172例临床分析[J].中华肝脏病杂志,2004,12(9):571-571. 被引量:31
  • 2上海医科大学《实用内科学》编辑委员会.实用内科学(第10版)[M].北京:人民卫生出版社,1997.1027.
  • 3桀本俊一,思地森一,周防武昭,他.药物性肝障害の诊断と治疗.肝胆肝萃,2000,40(6):887-897.
  • 4丰田隆谦,上野义之.Rifampicin诱导体の临床治疗效果と副作用,日本临床,2000,58(2):376-382.
  • 5Kaplovitz N.Drug-induced liver disorders:implications for drug development and regulation.Drug Saf,2001,24(7):483-490.
  • 6Farber JL,Kyle ME,Coleman JB.Mechanisms of cell injury by activated oxygen species.Lab Invest,1990,62 (6):670-679.
  • 7Hensley K,Robinson KA,Gabbita SP,et al.Reactive oxygen species,cell signaling,and cell injury.Free Radic Biol Med,2000,28(10):1456-1462.
  • 8Baydas G,Canatan H,Turkoglu A.Comparative analysis of the protective effects of melatonin and vitamin E on streptozotocin-induced diabetes mellitus.J pineal Res,2002,32 (4):225 -230.
  • 9Mora A,Paya M,Rios JL,et al.Structure-activity relationships of polymethoxyflavones and other flavonoids as inhibitors of non-enzymic lipid peroxidation.Biochem Pharmacol,1990,40 (4):793-797.
  • 10Marteau P,Ballet F,Chretien Y,et al.Effect of vasodilators on hepatic microcirculation:a study of the inhibition of norepinephrine-induced vasoconstriction in the isolated perfused rat liver.Hepatology,1988,8(2):228-231.

二级参考文献5

  • 1Turktas H, Unsal M, Tulek N, et al. Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazidand and pyrazinamide) or viral hepatitis.Tuber Lung Dis, 1994, 75: 58-60.
  • 2Jasmer RM, Daley CL. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe? Am J Respir Crit Care Med,2003, 167: 809-810.
  • 3Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf, 2001, 24: 483-490.
  • 4Kunimoto D, Warman A, Beckon A, et al. Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity. Clin Infect Dis, 2003, 36: 158-161.
  • 5Castro KG, Jereb JA, Koppaka VR, et al. Fatal liver injury associated with rifampin-pyrazinamide treatment of latent tuberculosis infection. Chest, 2003, 123: 967.

共引文献34

同被引文献17

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部